Total | UH | GH | PHC | P | SoM | P* | |
---|---|---|---|---|---|---|---|
N = 592 (%) | n = 125 (%) | n = 134 (%) | n = 194 (%) | n = 139 (%) | |||
Midwives screened | 112 (18.9) | 39 (31.2) | 26 (19.4) | 32 (16.5) | <0.01 | 15 (10.8) | <0.01 |
Type of test (N = 112) | NA | NA | |||||
Pap smear | 80 (13.5) | 29 (74.4) | 19 (73.1) | 27 (84.4) | 5 (33.3) | ||
VIA | 29 (4.9) | 8 (20.5) | 7 (26.9) | 5 (15.6) | 9 (60.0) | ||
Ignore it** | 3 (2.7) | 2 (5.1) | 0 (0.0) | 0 (0.0) | 1 (6.7) | ||
Practice of screening | |||||||
Propose screening to women | 223 (37.7) | 57 (45.6) | 62 (46.3) | 53 (27.3) | <0.01 | 51 (36.7) | <0.01 |
Had already performed visual inspection | 50 (8.4) | 12 (9.6) | 16 (11.9) | 11 (5.7) | 0.12 | 11 (7.9) | 0.22 |
Opinion on the HPV vaccine (N = 298) | |||||||
Protect against cervical cancer | 224 (75.2) | 64 (80.0) | 47 (79.7) | 75 (81.5) | 0.01 | 38 (56.7) | <0.01 |
Available in Côte d’Ivoire | 158 (53.0) | 42 (52.5) | 39 (66.1) | 47 (51.1) | 0.12 | 30 (44.8) | 0.11 |
Dangerous for health | 10 (3.4) | 2 (2.5) | 3 (5.1) | 4 (4.3) | NA | 1 (1.5) | NA |
Expensive | 8 (2.7) | 2 (2.5) | 2 (3.4) | 3 (3.3) | NA | 1 (1.5) | NA |
Will recommend it | 211 (70.8) | 59 (73.8) | 45 (76.3) | 74 (80.4) | 0.10 | 33 (49.3) | <0.01 |